No photo available
Our client is seeking a buyer for their company – the nation’s largest OssaTron® service provider – servicing over 450 hospitals and surgery centers in 42 states. OssaTron® is an FDA approved treatment for chronic plantar fasciitis and chronic lateral epicondylitis that has failed to respond to conservative treatments. The company is also the exclusive distributor of the dermaPACE® system, FDA cleared to treat diabetic foot ulcers that have not healed after four weeks of conservative care, to the Veteran's Administration, Indian Health Service, and tribally operated healthcare services throughout the United States. The company has $2.8 million in revenue with $1.4 million EBITDA.
Disclaimer: DealStream has not independently verified any of the information in this listing and makes no warranty as to its accuracy or completeness. This listing does not constitute an offer to sell, solicit or make an offer to buy an investment interest. Offers to sell, or the solicitation of offers to buy, any security can only be made through official offering documents, such as a subscription agreement and private placement memorandum.